• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Jan. 23, 2013

View Archived Issues

Facility Inspection a Sticking Point in Impax's Rytary CRL

The FDA issued a complete response letter to Impax Pharmaceuticals, of Hayward, Calif., a division of Impax Laboratories Inc., for Rytary (IPX066), indicating that a re-inspection of the company's Hayward facility pursuant to a warning letter issued in May 2011 is necessary before the new drug application (NDA) may be approved. Read More

Phase II Assets Gained Value, but Deals Lagged

A Deloitte Recap LLC analysis of 2012 biopharma dealmaking activity suggested a seller's market for Phase II assets, with median up-front cash of $35 million for market rights in transactions involving at least one major territory, up from a median of $30 million during the 2007-2011 time frame. However, market rights at other stages, including approval, lagged, as did the total deal flow. Read More

Gut Microbes, Sex Hormones, Autoimmune Risk Interrelated

Autoimmune diseases are one area where it's a man's world. "Many autoimmune diseases are much more frequent in females," Jayne Danska told BioWorld Today. "That's been known for decades. But we don't have any insight into how to take that insight and do something useful for women with it." Read More

Start-up Dezima Taking on Big Pharma in CETP Inhibition

Newly established Dutch start-up Dezima Pharma BV in-licensed what it considers a best-in-class cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (formerly TA-8995), from Osaka, Japan-based Mitsubishi Tanabe Pharma Corp. and is planning to move the cholesterol-lowering drug into a Phase II trial involving more than 400 patients in the coming months. Read More

Financings Roundup

• Sernova Corp., of London, Ontario, will make a nonbrokered private placement of $2 million to support use of its platform technology to develop therapies for diabetes and other diseases. Read More

Stock Movers

Read More

Other News To Note

• Progenics Pharmaceuticals Inc., of Tarrytown, N.Y., acquired Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass. Under the terms of the all-stock transaction, Progenics exchanged about 4.5 million shares of its common stock (8.9 percent of the total outstanding post-transaction shares) for all of the outstanding shares of Molecular Insight, which will become a wholly owned subsidiary of Progenics. Read More

Clinic Roundup

• Axelar AB, of Stockholm, Sweden, a Karolinksa Development AB portfolio firm, said an investigator-sponsored Phase I/II study started in the U.S. to test AXL1717, an oral small-molecule insulin-like growth factor 1 receptor inhibitor, in patients with malignant astrocytomas, a type of brain tumor. Read More

Pharma: Other News To Note

• Allergan Inc., of Irvine, Calif., said the FDA approved Botox (onabotulinumtoxinA) for the treatment of overactive bladder. Read More

Pharma: Clinic Roundup

• CSL Behring, of King of Prussia, Pa., said it enrolled the first patient in the pivotal pediatric Phase III trial to test efficacy and pharmacokinetics of recombinant fusion protein. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 12, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe